Targeting CD300ld to normalize the tumor microenvironment: an emerging insight in cancer immunotherapy

In a recent Nature elegant study, Wang et al. identified CD300ld, a novel functionally highly conserved tumor immunosuppressive receptor, highly expressed specifically on polymorphonuclear myeloid‐derived suppressor cells (PMN‐MDSCs), as well as a key receptor in the regulation of recruitment and immunosuppressive function of PMN‐MDSCs. Targeting CD300ld could remodel the tumor immune microenvironment, resulting in a broad‐spectrum anti‐tumor effect.